The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions Peptides may soon be easier to get amid RFK Jr.'s push, but experts warn of risks BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes The New York Times FDA takes first step in possible reversal of ban on some peptides The Washington Post The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York